Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, announced their partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) today to identify and develop high-quality monoclonal antibodies for promising Parkinson’s disease (PD) targets. The availability of rigorously validated, reproducible, and readily accessible antibody reagents that target PD-relevant proteins remains a key barrier to therapeutic development for Parkinson’s patients. As part of the partnership, CST and MJFF scientists will collaborate closely to identify promising PD targets and develop relevant, highly validated reagents to accelerate Parkinson’s disease research.
